

**A V E X A**

Avexa Limited
ABN 53 108 150 750
576 Swan Street Richmond
Victoria Australia 3121

Telephone 61 3 9208 4300
Facsimile 61 3 9208 4004
Website www.avexa.com.au

ASX Release

21 March 2007

Radio Broadcast

Avexa Limited wishes to announce that its CEO, Dr Julian Chick and Chief Scientific Officer, Dr Jonathan Coates, will make a presentation on **Avexa's Phase IIb results for apricitabine (ATC) and capital raising** on "Boardroomradio". The broadcast of the presentation will be at 2.00pm on Wednesday 21 March 2007.

The link for this presentation can be accessed at

<http://www.brr.com.au/event/AVX/1243/21400/wmp/ep4ncgilsk>

To listen, simply click on the Windows Media Player, QuickTime or MP3 icon.

Additionally, the presentation can be accessed at www.boardroomradio.com where it will also be archived for future on-demand listening- if you miss the live presentation, you can log on later to hear the news.

Yours sincerely
Avexa Limited

Company Secretary

For more information:

Dr. Julian Chick
Chief Executive Officer
+61 3 9208 4300

Mr Rod North
Bourse Communications
+ 61 (03) 9510-8309

www.avexa.com.au

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases, in particular diseases which have a significant unmet medical need. Avexa has dedicated resources and funding for key projects including antiviral drugs for HIV and an antibiotic alternative for antibiotic-resistant bacterial infections. The Company's lead program is apricitabine (ATC) which has recently successfully completed the 21 day dosing of its Phase IIb trial. The Company continues to progress ATC towards Phase III trials.